A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of tafluprost compared with latanoprost

Traverso C.E., Ropo A., Papadia M., Uusitalo H.

2010
Journal of Ocular Pharmacology and Therapeutics

View publication

Therapeutic Area

Glaucoma
Categories

Clinical development

Affiliations

Centro di Ricerca Clinica e Laboratorio per Il Glaucoma e la Cornea, University of Genova, Azienda Ospedaliera Universitaria San Martino, Largo R. Benzi Genova 10-16132, Italy; Santen Oy, Clinical Research, Helsinki, Finland; University of Kuopio, Kuopio, Finland; University of Tampere, Tampere University Hospital, Tampere, Finland

Related Publications

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.

Efficacy and Safety of a Preservative-Free Latanoprost Cationic Emulsion in Patients with Open-Angle Glaucoma and Concurrent Ocular Surface Disease: A Randomized Phase 2 Study.

Bacharach, Jason; McLaurin, Eugene B.; Silverstein, Steven; Amrane, Mourad; Garrigue, Jean-Sebastien; Ismail, Dahlia; Flynn, William J.; Catiolanze Phase 2 study group

Assessment of Brain-Derived Neurotrophic Factor on Retinal Structure and Visual Function in Rodent Models of Optic Nerve Crush

Taniguchi T.; Sharif N.A.; Ota T.; Farjo R.A.; Rausch R.

View all Glaucoma publications